Olema Pharmaceuticals (OLMA) Cash from Investing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash from Investing Activities data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 110.05% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was -$106.1 million, a 10.4% increase from a year earlier, with the FY2025 full-year figure at -$155.8 million, down 66.54% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $4.5 million, up from -$162.2 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for OLMA reached as high as $45.9 million in Q3 2024 and fell as low as -$162.2 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$9.3 million across 5 years, with a median of $14.1 million in 2023.
• Across the five-year window, Cash from Investing Activities sank 289.24% in 2023 and surged 801.8% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $16.3 million in 2022, then sank by 289.24% to -$30.9 million in 2023, then sank by 270.12% to -$114.4 million in 2024, then plunged by 41.74% to -$162.2 million in 2025, then surged by 102.79% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $4.5 million in Q1 2026, -$162.2 million in Q4 2025, and $17.3 million in Q3 2025.